Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


16 Items
Title  Creator  Group name  Publishing year 
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort Galvin et al. EquipeCTCS 2024-01
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program Le Du et al. EquipeCTCS 2023-10-03
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort Grinda et al. EquipeCTCS 2023-08
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial Huober et al. EquipeELC 2023-08-10
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial Bidard et al. EquipeCTCS 2023-11-06
Real-world evidence of the management and prognosis of young women (?40?years) with de novo metastatic breast cancer Mallet et al. EquipeELC 2022
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study Dalenc et al. EquipeELC 2022-03
Impact of body mass index on overall survival in patients with metastatic breast cancer Saleh et al. EquipePC 2021-02
Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort Pasquier et al. EquipeCTCS Jan 2020
Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study Heudel et al. EquipePC Jul 2020
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016 Deluche et al. EquipeCTCS 2020-04
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup D'Hondt et al. EquipePC Oct 18, 2019
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort Darlix et al. EquipeCTCS Dec 2019
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial Jacot et al. EquipeCTCS 11 14, 2019
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort Gobbini et al. EquipeCTCS Jun 2018
[Breast cancer screening: On our way to the future] Delaloge et al. EquipeCTCS 09 2016
16 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés